Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

221. Breast cancer in situ

Breast cancer in situ Breast cancer in situ - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Breast cancer in situ Last reviewed: August 2018 Last updated: June 2018 Summary Non-invasive cancer that originates in lobules or ducts. Typically asymptomatic and diagnosed at screening. Tamoxifen can be used to prevent ductal carcinoma in situ (DCIS) disease progression and lobular carcinoma in situ (LCIS) progression (...) to invasive carcinoma. Screening is recommended by most organisations issuing guidelines, in all women aged ≥40 years with annual bilateral mammography. Diagnosis is with mammography, supplemented with other imaging, such as ultrasound or magnetic resonance imaging, and biopsy. Some patients may decide to have preventative bilateral mastectomy. There are different approaches. Margin width remains something that is debated. Definition Breast cancer in situ is cancer that is confined to the duct or lobule

BMJ Best Practice2018

222. Primary invasive breast cancer

Primary invasive breast cancer Primary invasive breast cancer - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Primary invasive breast cancer Last reviewed: August 2018 Last updated: May 2018 Summary Breast cancer is a malignancy that is often strongly influenced by family history, hormonal exposure, and lifestyle factors. On physical examination, the patient usually demonstrates a firm mass, which may be associated (...) with axillary lymphadenopathy, skin changes, and nipple discharge. Given the widespread use of screening mammography, the asymptomatic patient may be diagnosed with breast cancer after abnormal calcifications and/or architectural distortion are noted on mammogram. Treatment requires a multi-disciplinary approach, involving breast surgeons, medical oncologists, and radiation oncologists. Complications of therapy are specific to each modality of treatment, and careful monitoring and preventive therapy

BMJ Best Practice2018

223. Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V

Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Ribociclib (Mammakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 December 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-45 Ribociclib (breast (...) cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-45 Version 1.0 Ribociclib (breast cancer) 13 December 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ribociclib (breast cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 5 September 2017 Internal

Institute for Quality and Efficiency in Healthcare (IQWiG)2018

224. Urban rural disparity in female breast cancer incidence rate in China and the increasing trend in parallel with socioeconomic development and urbanization in a rural setting

Urban rural disparity in female breast cancer incidence rate in China and the increasing trend in parallel with socioeconomic development and urbanization in a rural setting ORIGINAL ARTICLE Urban rural disparity in female breast cancer incidence rate in China and the increasing trend in parallel with socioeconomic development and urbanization in a rural setting Denggui Wen 1 , Xiaoduo Wen 1 , Yi Yang 2 , Yuetong Chen 1 , Lizhen Wei 1 , Yutong He 1 & Baoen Shan 1 1 Cancer Center, Fourth (...) Hospital of Hebei Medical University, Shijiazhuang, China 2 Department of Medical Imaging, Fourth Hospital of Hebei Medical University, Shijiazhuang, China Keywords Healthy diet; obesity and/or overweight; prevention of female breast cancer; socioeconomic development; urbanization. Correspondence Baoen Shan, Cancer Center, Fourth Hospital of Hebei Medical University, Jiankanglu 12, Shijiazhuang, Hebei 050011, China. Tel: +86 311 8609 5337 Fax: +86 311 8607 7634 Email: wshjw136@163.com Received: 26

Thoracic cancer2017 Full Text: Link to full Text with Trip Pro

225. Highlight report: Intratumoral metabolomic heterogeneity of breast cancer

Highlight report: Intratumoral metabolomic heterogeneity of breast cancer 29333137 2018 11 13 1611-2156 16 2017 EXCLI journal EXCLI J Highlight report: Intratumoral metabolomic heterogeneity of breast cancer. 1328-1329 10.17179/excli2017-1045 Stoeber Regina R IfADo - Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund, Ardeystr. 67, D-44139 Dortmund, Germany. eng Editorial 2017 12 22 Germany EXCLI J 101299402 1611-2156 Cancer Res. 2017 Sep 1;77(17 ):4589-4601 (...) 28652252 EXCLI J. 2015 Apr 14;14:540-1 26535042 NMR Biomed. 2012 Nov;25(11):1271-9 22407957 Cell Cycle. 2014;13(20):3282-91 25485508 NMR Biomed. 2010 May;23(4):424-31 20101607 PLoS One. 2013 Dec 19;8(12):e83866 24367616 NMR Biomed. 2012 Feb;25(2):369-78 21823183 PLoS One. 2016 Dec 7;11(12 ):e0167585 27926932 Anticancer Res. 2015 Oct;35(10):5277-85 26408687 J Cancer Res Clin Oncol. 2017 Jul;143(7):1123-1131 28251349 Mod Pathol. 2017 Jul;30(7):964-977 28281552 Medicine (Baltimore). 2016 Apr;95(15):e3398

EXCLI journal2017 Full Text: Link to full Text with Trip Pro

226. Biomarkers of aging associated with past treatments in breast cancer survivors

Biomarkers of aging associated with past treatments in breast cancer survivors ARTICLE OPEN Biomarkers of aging associated with past treatments in breast cancer survivors Zorica Scuric 1 , Judith E. Carroll 2,3,4 , Julienne E. Bower 2,3,4,5 , Sam Ramos-Perlberg 1 , Laura Petersen 4 , Stephanie Esquivel 2,3 , Matt Hogan 1 , Aaron M. Chapman 1 , Michael R. Irwin 2,3 , Elizabeth C. Breen 2,3 , Patricia A. Ganz 1,4 and Robert Schiestl 1,2,6 Radiation and chemotherapy are effective treatments (...) for cancer, but are also toxic to healthy cells. Little is known about whether prior exposure to these treatments is related to markers of cellular aging years later in breast cancer survivors. We examined whether past exposure to chemotherapy and/or radiation treatment was associated with DNA damage, telomerase activity, and telomere length 3–6 years after completion of primary treatments in breast cancer survivors (stage 0–IIIA breast cancer at diagnosis). We also examined the relationship

NPJ breast cancer2017 Full Text: Link to full Text with Trip Pro

227. Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer.

Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer. Importance: Application of deep learning algorithms to whole-slide pathology images can potentially improve diagnostic accuracy and efficiency. Objective: Assess the performance of automated deep learning algorithms at detecting metastases in hematoxylin and eosin-stained tissue sections of lymph nodes of women with breast cancer and compare it with pathologists' diagnoses (...) in a diagnostic setting. Design, Setting, and Participants: Researcher challenge competition (CAMELYON16) to develop automated solutions for detecting lymph node metastases (November 2015-November 2016). A training data set of whole-slide images from 2 centers in the Netherlands with (n = 110) and without (n = 160) nodal metastases verified by immunohistochemical staining were provided to challenge participants to build algorithms. Algorithm performance was evaluated in an independent test set of 129 whole

JAMA2017 Full Text: Link to full Text with Trip Pro

228. Sentinel Lymph Node Biopsy Pathology and 2-Year Postsurgical Recurrence of Breast Cancer in Kenyan Women

Sentinel Lymph Node Biopsy Pathology and 2-Year Postsurgical Recurrence of Breast Cancer in Kenyan Women ');//--> ');//--> Search in: Menu Captcha ASCO Family of Sites Journals Publications Education Other Sites 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology |

Journal of global oncology2017 Full Text: Link to full Text with Trip Pro

229. Contemporary Hormonal Contraception and the Risk of Breast Cancer.

Contemporary Hormonal Contraception and the Risk of Breast Cancer. BACKGROUND: Little is known about whether contemporary hormonal contraception is associated with an increased risk of breast cancer. METHODS: We assessed associations between the use of hormonal contraception and the risk of invasive breast cancer in a nationwide prospective cohort study involving all women in Denmark between 15 and 49 years of age who had not had cancer or venous thromboembolism and who had not received (...) treatment for infertility. Nationwide registries provided individually updated information about the use of hormonal contraception, breast-cancer diagnoses, and potential confounders. RESULTS: Among 1.8 million women who were followed on average for 10.9 years (a total of 19.6 million person-years), 11,517 cases of breast cancer occurred. As compared with women who had never used hormonal contraception, the relative risk of breast cancer among all current and recent users of hormonal contraception was

NEJM2017

230. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity ARTICLE OPEN A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germlineBRCA mutation demonstrates marked activity J. K. Litton 1 , M. Scoggins 2 , D. L. Ramirez 1 , R. K. Murthy 1 , G. J. Whitman 2 , K. R. Hess 3 , B. E. Adrada 2 , S. L. Moulder 1 , C. H. Barcenas 1 , V. Valero 1 , J. Schwartz Gomez 1 , E (...) . A. Mittendorf 4 , A. Thompson 4 , T. Helgason 1 , G. B. Mills 5 , H. Piwnica-Worms 6 and B. K. Arun 1 This study was undertaken to determine the feasibility of enrolling breast cancer patients on a single-agent-targeted therapy trial before neoadjuvant chemotherapy. Speci?cally, we evaluated talazoparib in patients harboring a deleterious BRCA mutation (BRCA +). Patients with a germline BRCA mutation and=1cm, HER2-negative primary tumors were eligible. Study participants underwent a pretreatment biopsy, 2

NPJ breast cancer2017 Full Text: Link to full Text with Trip Pro

231. In Their Own Words: A Qualitative Study of Kenyan Breast Cancer Survivors’ Knowledge, Experiences, and Attitudes Regarding Breast Cancer Genetics

In Their Own Words: A Qualitative Study of Kenyan Breast Cancer Survivors’ Knowledge, Experiences, and Attitudes Regarding Breast Cancer Genetics ');//--> ');//--> Search in: Menu Captcha ASCO Family of Sites Journals Publications Education Other Sites 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology |

Journal of global oncology2017 Full Text: Link to full Text with Trip Pro

233. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology?Cancer Care Ontario Focused Guideline Update

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology?Cancer Care Ontario Focused Guideline Update | Cancer Care Ontario Google Tag Manager You are using an outdated browser. We suggest you update your browser for a better experience. for update. Browse Guidelines Browse Pathway Maps Sort by You are here / / Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline (...) Update Guidelines & Advice Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update ID: GL-1-A-2016-2 Oct 2017 Type of Content: Guidelines & Advice, Clinical Document Status: Current Authors: Catherine Van Poznak, Mark R. Somerfield, William E. Barlow, J. Sybil Biermann, Linda D. Bosserman, Mark J. Clemons, Sukhbinder K. Dhesy-Thind, Melissa S. Dillmon, Andrea Eisen, Elizabeth S. Frank, Reshma Jagsi, Rachel

Cancer Care Ontario2017

234. Bevacizumab (Kyomarc) - for the treatment of cancer of the colon or rectum, breast cancer, non-small cell lung cancer (NSCLC), kidney cancer, cervical cancer, and cancer of the ovary, the fallopian tube, or the peritoneum.

Bevacizumab (Kyomarc) - for the treatment of cancer of the colon or rectum, breast cancer, non-small cell lung cancer (NSCLC), kidney cancer, cervical cancer, and cancer of the ovary, the fallopian tube, or the peritoneum.

European Medicines Agency - EPARs2017

235. Palbociclib (breast cancer) - Addendum to commission A16-74

Palbociclib (breast cancer) - Addendum to commission A16-74 1 Translation of addendum A17-15 Palbociclib (Mammakarzinom) – Addendum zum Auftrag A16-74 (Version 1.0; Status: 28 April 2017). Please note: This translation is provided as a service by IQWiG to English- language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 28 April 2017 1.0 Commission: A17-15 Version: Status: IQWiG Reports – Commission No. A17-15 Palbociclib (breast (...) cancer) – Addendum to Commission A16-74 1 Addendum A17-15 Version 1.0 Palbociclib – Addendum to Commission A16-74 28 April 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Palbociclib (breast cancer) – Addendum to Commission A16-74 Commissioning agency: Federal Joint Committee Commission awarded on: 12 April 2017 Internal Commission No.: A17-15 Address of publisher: Institut für Qualität und

Institute for Quality and Efficiency in Healthcare (IQWiG)2017

236. Effect of myofascial techniques for treatment of persistent arm pain after breast cancer treatment: randomized controlled trial

Effect of myofascial techniques for treatment of persistent arm pain after breast cancer treatment: randomized controlled trial 28914087 2017 09 15 1477-0873 2017 Sep 01 Clinical rehabilitation Clin Rehabil Effect of myofascial techniques for treatment of persistent arm pain after breast cancer treatment: randomized controlled trial. 269215517730863 10.1177/0269215517730863 To investigate the effect of myofascial therapy in addition to a standard physical therapy program for treatment (...) of persistent arm pain after finishing breast cancer treatment. Double-blinded (patient and assessor) randomized controlled trial. University Hospitals Leuven, Belgium. A total of 50 patients with persistent arm pain and myofascial dysfunctions after breast cancer treatment. Over three months, all patients received a standard physical therapy program. The intervention group received in addition 12 sessions of myofascial therapy, and the control group received 12 sessions of placebo therapy. Main outcome

EvidenceUpdates2017

237. Fulvestrant (Faslodex) - Treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer

Fulvestrant (Faslodex) - Treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer Published 11 December 2017 Statement of Advice: fulvestrant 250 mg solution for injection (Faslodex ® ) SMC No 1294/17 AstraZeneca UK Limited 10 November 2017 ADVICE: in the absence of a submission from the holder of the marketing authorisation fulvestrant (Faslodex ® ) is not recommended for use within NHS Scotland. Indication under review: Treatment of oestrogen receptor positive (...) , locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium. It is provided to inform

Scottish Medicines Consortium2017

238. Mesenchymal stem cells in breast cancer: response to chemical and mechanical stimuli

Mesenchymal stem cells in breast cancer: response to chemical and mechanical stimuli 158 www.impactjournals.com/oncoscience Oncoscience www.impactjournals.com/oncoscience/ Oncoscience, Vol. 4(11-12), November 2017 Mesenchymal stem cells in breast cancer: response to chemical and mechanical stimuli Seiichiro Ishihara, Suzanne M. Ponik, and Hisashi Haga The tumor microenvironment contains not only cancer cells but also non-cancerous cells and extracellular matrices (ECMs). These cell types (...) interact through chemical and mechanical stimuli and as a result, regulate tumor progression. While many studies have identified chemical stimuli that are critical for cancer progression, the role of mechanical stimuli is less defined. It has been recently shown that mechanical stimuli, especially the stiffness of ECMs, contribute to tumor progression in some specific cancers including breast, colorectal, and lung [1, 2, 3]. In particular, cancer cells respond to stiffness of surrounding ECMs

Oncoscience2017 Full Text: Link to full Text with Trip Pro

239. Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy

Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy ARTICLE OPEN Molecular changes in premenopausal oestrogen receptor- positive primary breast cancer in Vietnamese women after oophorectomy Ben P. Haynes 1 , Ophira Ginsburg 2,3 , Qiong Gao 4 , Elizabeth Folkerd 1 , Maria Afentakis 1 , Le Hong Quang 5 , Pham Thi Han 6 , Pham Hong Khoa 5 , Nguyen Van Dinh 5 ,TaVanTo 6 , Mark Clemons 7 , Ian E. Smith 8 and Mitch Dowsett 1,4 (...) For premenopausal women with primary ER+breast cancer, oophorectomy (OvX) is an evidence-based cost-effective option and is standard treatment in many countries. However, there is virtually no data describing the effects of OvX on breast tumour biology. We therefore, characterised the endocrine and genome-wide transcriptional impact of OvX in 56 premenopausal women with ER+ breastcancerfor2weekspriortomastectomy.Plasmaestradiolconcentrationsdecreasedfrom406±41to20.7±2.6pmol/l(mean ±sem) 24h after OvX

NPJ breast cancer2017 Full Text: Link to full Text with Trip Pro

240. PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells

PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells ARTICLE OPEN PTK6 regulates growth and survival of endocrine therapy- resistant ER+ breast cancer cells Koichi Ito 1 , Sun Hee Park 1 , Igor Katsyv 2 , Weijia Zhang 3 , Carmine De Angelis 4,5 , Rachel Schiff 4,5,6 and Hanna Y. Irie 1,7 The non-receptor tyrosine kinase, PTK6/BRK, is highly expressed in multiple tumor types, including prostate, ovarian, and breast cancers, and regulates oncogenic phenotypes (...) such as proliferation, migration, and survival. PTK6 inhibition also overcomes targeted therapy resistance of HER2+ breast cancer. Although PTK6 is highly expressed in ER+ Luminal breast cancers, the role of PTK6 in this subtype has not been elucidated. In this study, we investigated the functions of PTK6 in ER+ Luminal breast cancer cells, including those that are relatively resistant to estrogen deprivation or targeted endocrine therapies used in the treatment of ER+ cancers. Enhanced expression of PTK6 in ER

NPJ breast cancer2017 Full Text: Link to full Text with Trip Pro